• Goodheart MJ, Rose SL, Hatterman-Zogg M, Smith BJ, DeYoung BR, and Buller RE. BRCA2 alteration is important in clear cell carcinoma of the ovary. Clinical Genetics, In Press, 2009.
• Bradford L, Schwartz K, and Rose SL. Primary angiosarcoma of the ovary-a case report and review of the literature. Archives of Gynecology and Obstetrics, In Press, 2009.
• Rose SL. The Notch signaling pathway in ovarian cancer. International Journal of Gynecologic Cancer, In Press, 2009.
• Watts GS, Futscher BW, Holtan N, DeGeest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Medical Genomics, Sep 30, 2008;1:47.
• DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clinical Cancer Research, June 15, 2006;12(12):3730-3739.
• DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE, Friedman SL, Walsh MJ, Martignetti JA. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene, May 15, 2006.
• Rose SL, Fitzgerald MP, White NO, Hitchler MJ, Futscher BW, De Geest K, Domann FE. Epigenetic Regulation of Maspin Expression in Human Ovarian Carcinoma Cells. Gynecologic Oncology 102(2):319-324, 2006.
• Bradley SL, Rose SL, Lutgendorf SK, Costanzo ES, Anderson B. Quality of Life and Mental Health in Cervical and Endometrial Cancer Survivors. Gynecologic Oncology 100(3):479-486, 2006.
• Rose SL, Bunten CE, Geisler JP, Sood AK, Sorosky JI. Polypropylene mesh erosion into the bowel and vagina following abdominal sacral colpopexy. The Journal of Pelvic Medicine & Surgery, 12:1;45-47, 2006.
• Costanzo ES, Lutgendorf SK, Bradley SL, Rose SL, Anderson B. Cancer Attributions, Distress, and Health Practices Among Gynecologic Cancer Survivors. Psychosomatic Medicine 67(6):972-80, 2005.
• Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, DeYoung BR, Buller RE. The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer. Clinical Cancer Research 11:3733-3742, 2005.
• Geisler JP, Manahan KM, Geisler HE, Tammela JE, Rose SL, Hiett AK, Miller GA, Wiemann MC, Zhou Z. Heat Shock Protein 27 in the Placentas of Women with and without Severe Pre-eclampsia. Clinical and Experimental Obstetrics and Gynecology 31(1):12-14, 2004.
• Rose SL, Robertson AD, Goodheart MJ, DeYoung BR, Smith BJ, Buller RE. The Impact of p53 Structural Alteration on Ovarian Cancer Survival. Clinical Cancer Research 9: 4139-4144, 2003.
• Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Blake LM, Buller RE. P21 Expression is an Independent Prognostic Factor in p53 Null Ovarian Carcinoma. Clinical Cancer Research 9:1028-1032, 2003.
• Stone PJB, Goodheart MJ, Rose SL, Smith BJ, DeYoung BR, Buller RE. The Influence of Microvessel Density on Ovarian Carcinogenesis. Gynecologic Oncology 90: 566-571, 2003.
• Rose SL, Sorosky JI. Cervical Carcinoma Complicating Pregnancy. Postgraduate Obstetrics & Gynecology Vol.23, No.11, 1-7, 2003.
• Rose SL, Buller RE. The Role of p53 Mutation in BRCA1-Associated Ovarian Cancer. Minerva Ginecologica 54:201-209, 2002.
• Geisler JP, Rose SL, Mernitz CS, Warner JL, Hiett AK. Non-Gynecologic Laparoscopy in Second and Third Trimester Pregnancy: Obstetric Implications. J Laparoendo Surg 2:235-8, 1998.

Book Chapters

• Rose SL. “TP53/p53 as a prognostic factor” Prognostic and Predictive Factors in Gynecologic Cancers. Ed. Levenback CF, Sood AK, Lu KH, and Coleman RL. London: Informa UK Ltd., 2007. 45-62.

Abstracts

• Rose SL, Kunnimalaiyaan K, Seiler N. The role of Notch 1 in Ovarian cancer. The 40th Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, TX, 2009
• Seiler N, Kunnimalaiyaan K, Krichevsky L, Rose SL. ZM336372 suppresses growth in ovarian cancer cells by phosphorylation of GSK-3. The 4th Annual Academic Surgical Congress, Ft. Myers, FL, 2009.
• Rose SL, Greenblatt D, Seiler N, Chen H. Notch1 Down-Regulation by Gamma-secretase Inhibition Decreases Ovarian Cancer Cell Growth. The 3rd Annual Academic Surgical Congress, Huntington Beach, CA, February, 2008.
• Rose SL, Watts GS, Holtan N, DeGeest K, Domann FE, Futscher BW. Epigenomic patterns in Ovarian cancer. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2006.
• DiFeo AV, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Nishio H, Rose SL, Yao S, Levine A, Kalir T, Friedman SL, Walsh M, Buller RE, Martignetti JA. KLF6 and KLF6-SV1 regulate ovarian cancer progression and dissemination: Identification of a novel KLF6/E-cadherin pathway. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2006.
• Rose SL, Watts GS, Holtan N, DeGeest K, Domann FE, Futscher BW. Epigenomic patterns in Ovarian cancer. The University of Iowa Research Week, Iowa City, IA, 2006.
• Rose SL, Watts GS, Holtan N, DeGeest K, Domann FE, Futscher BW. Epigenomic patterns in Ovarian cancer. 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006.
• Rose SL, Fitzgerald MP, De Geest K, White N, Smith BJ, Domann FE. Maspin Expression is Activated by Loss of Promoter Methylation in Ovarian Carcinoma. The University of Iowa Research Week, Iowa City, IA, 2005.
• Rose SL, Fitzgerald MP, De Geest K, White N, Smith BJ, Domann FE. Maspin Expression is Activated by Loss of Promoter Methylation in Ovarian Carcinoma. Late-Breaking Poster Session. The 96th Annual Meeting of the American Association for Cancer Research, Anaheim, CA, 2005.
• Rose SL, Fitzgerald MP, De Geest K, White N, Smith BJ, Domann FE. Maspin Expression is Activated by Loss of Promoter Methylation in Ovarian Carcinoma. The 2005 National Gynecologic Oncology Fellows’ Forum, Tucson, AZ, 2005.
• Goodheart MJ, Rose SL, Smith NJ, De Geest K. Microvessel Density is a Marker of Biological Difference between Mucinous and Non-Mucinous Epithelial Ovarian Carcinoma. 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005.
• Goodheart MJ, Rose SL, Hatterman-Zogg MA, Smith B, DeYoung BR, Sorosky JI, Buller RE. BRCA2 Alteration is Important in Clear Cell Carcinoma of the Ovary. 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.
• Bradley SL, Rose SL, Costanzo E, Anderson B, Lutgendorf SK. Depression and Mood in Long-Term Survivors of Cervical and Endometrial Cancer. 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.
• Rose SL, Bradley SL, Lutgendorf SK, Sorosky JI, Anderson B. The Impact of Adjuvant Radiation Therapy on Long-Term Quality of Life in Patients with Stage I Endometrial Cancer. 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.
• Rose SL, Bradley SL, Lutgendorf SK, Sorosky JI, Anderson B. Long-Term Quality of Life in Cervical Cancer Survivors. 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004.
• Goodheart MJ, Rose SL, Hatterman-Zogg MA, Smith BJ, DeYoung BR, Sorosky JI, Buller RE. Understanding BRCA2 Dysfunction in Clear Cell Carcinoma of the Ovary. 18th Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, Durham, NC, October, 2003.
• Rose SL, Bradley SL, Sorosky JI, Anderson B, Lutgendorf S. Long-Term Quality of Life in Cervical Cancer Survivors. 18th Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, Durham, NC, October, 2003.
• Rose SL, Robertson AD, Goodheart MJ, Smith BJ, DeYoung BR, Buller RE. P53 Protein Structural Alteration Alone does not Impact Ovarian Cancer Survival. 94th Annual Meeting of the American Association for Cancer Research, Washington D.C., July, 2003.
• Geisler JP, Rose SL, Buller RE, Manahan KJ. Estrogen receptor and Expression in a case matched series of Serous and Endometrioid Adenocarcinomas of the Ovary. 94th Annual Meeting of the American Association for Cancer Research, Washington, D.C., July, 2003.
• Goodheart MJ, Rose SL, Fruehauf JP, Smith BJ, Anderson B, Buller RE, Sorosky JI. The Relationship of Thrombospondin-1 to Risk Factors in Ovarian Carcinoma. 32nd Annual Meeting of the Western Association of Gynecologic Oncologists, Steamboat Springs, CO, June, 2003.
• Geisler JP, Rose SL, Manahan KJ, Sorosky JI, Anderson B, Buller RE, Sood AK. Operative and Short Term Complications of Tunneled Central Venous Catheters on a Gynecologic Oncology Service. 34th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA, January, 2003.
• Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Blake LM, Buller RE. The Relationship between p21 Expression and p53 Gene Mutation Impacts Ovarian Cancer Survival. 31st Annual Meeting of the Western Association of Gynecologic Oncologists, Newport Beach, CA, June, 2002.
• Rudolph-Owen LA, Pradines J, Rose S, Buller RE. Analysis of Transcriptional Profiling Data by Detection of Activity Centers in Cellular Pathways in Ovarian Clinical Tissues With Known p53 and BRCA1 Status. 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April, 2002.
• Goodheart MJ, Rose SL, Geisler JP, Ritchie JM, Fruehauf JP, DeYoung BR, Buller, RE. The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer. 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, March, 2002.